Ranbaxy Unveils Virol, Anti-Aids Drug

Ranbaxy Laboratories Ltd has launched abacavir, an anti-retroviral drug, today. The drug, launched for the first time in India, will be marketed under the brand name Virol as a 300 mg tablet.

Industry sources anticipate the market share for abacavir to be around Rs 1.5 to Rs 2 crore in the first year itself.

More players are likely to enter the market with this drug. The size of the market for anti-retrovirals in India is around Rs 30 crore.

Ranbaxy has a market share of around 10 per cent in this segment, with Cipla being the major player with a 75 per cent market share.

 

Malvinder Mohan Singh, regional director (India), Ranbaxy Laboratories, said: